- Home
- THAR vs ATRA Comparison
THAR vs ATRA Comparison
Compare THAR & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THAR | ATRA |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.8M | 129.4M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | THAR | ATRA |
|---|---|---|
| Price | $2.96 | $5.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 495.8K | ★ 678.5K |
| Earning Date | 11-12-2025 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.97 |
| Revenue | N/A | ★ $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.54 |
| Revenue Growth | N/A | ★ 51.27 |
| 52 Week Low | $0.95 | $4.20 |
| 52 Week High | $9.08 | $19.15 |
Technical Indicators
Market Signals| Indicator | THAR | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 28.82 |
| Support Level | $2.71 | $4.20 |
| Resistance Level | $3.05 | $5.19 |
| Average True Range (ATR) | 0.23 | 1.52 |
| MACD | -0.01 | -0.76 |
| Stochastic Oscillator | 31.51 | 7.59 |
Price Performance
Historical ComparisonAbout THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).